RT Journal Article
SR Electronic
T1 Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of Long-Term Care Facilities in the VIVALDI study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.01.23286627
DO 10.1101/2023.03.01.23286627
A1 Stirrup, Oliver
A1 Shrotri, Madhumita
A1 Adams, Natalie L.
A1 Krutikov, Maria
A1 Azmi, Borscha
A1 Monakhov, Igor
A1 Tut, Gokhan
A1 Moss, Paul
A1 Hayward, Andrew
A1 Copas, Andrew
A1 Shallcross, Laura
YR 2023
UL http://medrxiv.org/content/early/2023/03/03/2023.03.01.23286627.abstract
AB We evaluated the effectiveness of 1-3 booster vaccinations against SARS-CoV-2 related mortality among a cohort of 13407 older residents of long-term care facilities (LTCFs) participating in the VIVALDI study in England in 2022. Cox regression was used to estimate relative hazards of SARS-CoV-2 related death following booster vaccination relative to 2 doses (after 84+ days), stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF capacity. Each booster provided additional short-term protection relative to primary vaccination, with consistent pattern of waning to 45-75% reduction in risk beyond 112 days.Competing Interest StatementLS reports grants from the Department of Health and Social Care during the conduct of the study and is a member of the Social Care Working Group, which reports to the Scientific Advisory Group for Emergencies. AH reports funding from the COVID Core Studies Programme and is a member of the New and Emerging Respiratory Virus Threats Advisory Group at the Department of Health and Environmental Modelling Group of the Scientific Advisory Group for Emergencies. All other authors declare no competing interests.Funding StatementThis work is independent research funded by the Department of Health and Social Care (COVID-19 surveillance studies). MK is funded by a Wellcome Trust Clinical PhD Fellowship (222907/Z/21/Z). LS is funded by a National Institute for Health Research Clinician Scientist Award (CS-2016-007). AH is supported by Health Data Research UK (LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient consent was not obtained for data use other than for those patients who underwent blood sampling specifically for the VIVALDI study. The legal basis to access data from residents without informed consent is provided by Health Research Authority Confidentiality Advisory Group approval (21/CAG/0156). Ethical approval was obtained from South Central-Hampshire B Research Ethics Committee (20/SC/0238).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDe-identified test results and limited meta-data will be made available for use by researchers in future studies, subject to appropriate research ethical approvals, once the VIVALDI study cohort has been finalised.